» Articles » PMID: 11070088

Myocardial Extracellular Matrix Remodeling in Transgenic Mice Overexpressing Tumor Necrosis Factor Alpha Can Be Modulated by Anti-tumor Necrosis Factor Alpha Therapy

Overview
Specialty Science
Date 2000 Nov 9
PMID 11070088
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

Myocardial fibrosis caused by maladaptive extracellular matrix (ECM) remodeling is implicated in the dysfunction of the failing heart. Matrix metalloproteinases (MMPs) regulate ECM remodeling, and are regulated by cytokines. Transgenic mice with cardiac-specific overexpression of tumor necrosis factor alpha (TNF-alpha) (TNF1.6) develop heart failure. We hypothesized that modulation of TNF-alpha and/or MMP activity might alter the myocardial ECM remodeling process and the development of heart failure. To test this hypothesis, we took advantage of the TNF1.6 mice and studied soluble and total collagens and collagen type profiling by using hydroxyproline quantification, Sircol collagen assay, Northern blot analysis, and immunohistochemistry and studied myocardial function by using echocardiography. Progressive ventricular hypertrophy and dilation in the TNF1.6 mice were accompanied by a significant increase in MMP-2 and MMP-9 activity, an increase in collagen synthesis, deposition, and denaturation, and a decrease in undenatured collagens. In young TNF1.6 mice, these changes in the ECM were associated with marked diastolic dysfunction as demonstrated by significantly reduced transmitral Doppler echocardiographic E/A wave ratio. Anti-TNF-alpha treatment with adenoviral vector expressing soluble TNF-alpha receptor type I attenuated both MMP-2 and MMP-9 activity, prevented further collagen synthesis, deposition and denaturation, and preserved myocardial diastolic function in young, but not old, TNF1.6 mice. The results suggest a critical role of TNF-alpha and MMPs in myocardial matrix remodeling and functional regulation and support the hypothesis that both TNF-alpha and MMPs may serve as potential therapeutic targets in the treatment of heart failure.

Citing Articles

Systemic inflammation is associated with myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy.

Guo X, Zhang J, Huang M, Song C, Nie C, Zheng X ESC Heart Fail. 2024; 12(1):582-591.

PMID: 39417989 PMC: 11769645. DOI: 10.1002/ehf2.15109.


Inflammation in Heart Failure-Future Perspectives.

Arvunescu A, Ionescu R, Cretoiu S, Dumitrescu S, Zaharia O, Nanea I J Clin Med. 2023; 12(24).

PMID: 38137807 PMC: 10743797. DOI: 10.3390/jcm12247738.


Blockade of Inflammatory Markers Attenuates Cardiac Remodeling and Fibrosis in Rats with Supravalvular Aortic Stenosis.

Duchatsch F, Miotto D, Tardelli L, Dionisio T, Campos D, Santos C Biomedicines. 2023; 11(12).

PMID: 38137440 PMC: 10740498. DOI: 10.3390/biomedicines11123219.


Effects of Inflammatory Cell Death Caused by Catheter Ablation on Atrial Fibrillation.

Liu D, Li Y, Zhao Q J Inflamm Res. 2023; 16:3491-3508.

PMID: 37608882 PMC: 10441646. DOI: 10.2147/JIR.S422002.


More than just a small left ventricle: the right ventricular fibroblast and ECM in health and disease.

McNair B, Shorthill S, Bruns D Am J Physiol Heart Circ Physiol. 2023; 325(2):H385-H397.

PMID: 37389951 PMC: 10396282. DOI: 10.1152/ajpheart.00213.2023.


References
1.
Maquart F, Bellon G, Chaqour B, Wegrowski J, Patt L, Trachy R . In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993; 92(5):2368-76. PMC: 288419. DOI: 10.1172/JCI116842. View

2.
Litwin S, Grossman W . Diastolic dysfunction as a cause of heart failure. J Am Coll Cardiol. 1993; 22(4 Suppl A):49A-55A. DOI: 10.1016/0735-1097(93)90463-b. View

3.
Galis Z, Muszynski M, Sukhova G, Libby P . Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci. 1995; 748:501-7. DOI: 10.1111/j.1749-6632.1994.tb17348.x. View

4.
Weber K, Brilla C, Campbell S, Zhou G, Matsubara L, Guarda E . Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press. 1992; 1(2):75-85. DOI: 10.3109/08037059209077497. View

5.
Dollery C, McEwan J, Henney A . Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995; 77(5):863-8. DOI: 10.1161/01.res.77.5.863. View